NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

mRNA疫苗及治療藥的全球市場 (2021-2031年):市場預測 (用途、mRNA類型、各國)、競爭環境

Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031

出版商 BIS Research Inc. 商品編碼 1004970
出版日期 內容資訊 英文 207 Pages
商品交期: 最快1-2個工作天內
價格
mRNA疫苗及治療藥的全球市場 (2021-2031年):市場預測 (用途、mRNA類型、各國)、競爭環境 Global mRNA Vaccines and Therapeutics Market: Focus on Application, mRNA Type, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031
出版日期: 2021年05月07日內容資訊: 英文 207 Pages
簡介

全球新型冠狀病毒感染疾病 (COVID-19) 疫苗mRNA疫苗及治療藥的市場規模預計從2021年到2025年顯示-13.50%的年複合成長率。

還有非COVID-19疫苗mRNA疫苗及治療藥的市場預計從2026到2031年,以95.49%的年複合成長率成長。全球的COVID-19感染者數增加,良好的法規環境,mRNA為基礎的COVID-19疫苗開發的大數量外部資金提供等要素促進該市場的成長。

本報告提供全球mRNA疫苗及治療藥的市場調查,市場定義和概要,市場影響因素分析,法律制度,市場規模的變化、預測,用途、mRNA類型、地區等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

摘要整理

第1章 產品定義

第2章 市場範圍

第3章 調查手法

第4章 市場概要

  • 市場定義
  • mRNA為基礎的疫苗:目前形勢與未來的可能性
  • 市場足跡、成長可能性
    • COVID-19疫苗用
    • 非COVID-19疫苗用

第5章 產業考察

  • 概要
  • 法律上的必要條件、架構:美國
  • 法律上的必要條件、架構:歐洲
  • 法律上的必要條件、架構:亞太地區

第6章 市場動態

  • 概要
  • 影響分析
  • 市場推動因素
  • 市場抑制因素
  • 市場機會

第7章 競爭情形

  • 主要策略、展開
  • 企業佔有率分析

第8章 市場分析、預測:各用途

  • COVID-19用mRNA疫苗
    • 概要
    • 已上市疫苗
    • 開發平台疫苗
  • 非COVID-19用mRNA疫苗
    • 概要
    • 腫瘤
    • 感染疾病
    • 其他

第9章 市場分析、預測:mRNA各類型

  • 概要
  • COVID-19用:mRNA各類型
    • 核苷修飾mRNA(modRNA)
    • 未修飾mRNA
    • 自我放大mRNA
  • 非COVID-19用:mRNA各類型
    • 核苷修飾mRNA(modRNA)
    • 未修飾mRNA
    • 自我放大mRNA

第10章 市場分析、預測:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他地區

第11章 企業簡介

  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited.
  • ethris GmbH
  • GlaxoSmithKline plc
  • Gennova Biopharmaceuticals Ltd
  • Moderna, Inc.
  • Pantherna Therapeutics GmbH
  • Providence Therapeutics
  • Silence Therapeutics
  • Translate Bio
  • VERSAMEB AG
  • Verve Therapeutics, Inc.
目錄
Product Code: BHP1071SA

Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines and Non-COVID-19 Vaccines to Reach $28.92 Billion and $1.69 Billion by 2025 and 2031, Respectively; BIS Research Study

Market Report Coverage - mRNA Vaccines and Therapeutics

Market Segmentation

  • Application - COVID-19 mRNA Vaccines and Non-COVID-19 mRNA Vaccines
  • mRNA Type - Nucleoside-Modified mRNA, Unmodified mRNA, and Self-Amplifying mRNA

Regional Segmentation

  • North America - U.S., and Canada
  • Europe - Germany, France, U.K., Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - China, Japan, South Korea, Australia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

Growth Drivers

  • Growing Cases of COVID-19 Globally
  • Favorable Regulatory Environment
  • Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines

Market Challenges

  • Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines
  • High Price Associated with mRNA-Based COVID-19 Vaccines

Market Opportunities

  • Growing Emphasis on Research and Development for Non-COVID-19 Applications

Key Companies Profiled

Arcturus Therapeutics Holdings Inc., BioNTech SE, CureVac N.V., Daiichi Sankyo Company, Limited., ethris GmbH, GlaxoSmithKline plc, Gennova Biopharmaceuticals Ltd, Moderna, Inc., Pantherna Therapeutics GmbH, Providence Therapeutics, Silence Therapeutics, Translate Bio, VERSAMEB AG, and Verve Therapeutics, Inc.

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the global mRNA vaccines and therapeutics market?
  • What are the key development strategies being implemented by the major players in order to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for the global mRNA vaccines and therapeutics market?
  • How is each segment of the market expected to grow during the forecast period, 2021-2031?
  • Who are the leading players with significant offerings to the global mRNA vaccines and therapeutics market, and what is the expected market dominance for each of these leading players?
  • What are the adoption trends for mRNA vaccines and therapeutics in established economies and emerging economies across the world?
  • Which companies are anticipated to be highly disruptive in the future, and why?
  • What are the current clinical unmet needs that are being faced in the global mRNA vaccines and therapeutics market?
  • What are the dynamics of various application areas and countries, which are impacting the global mRNA vaccines and therapeutics market?
  • What are the new market opportunities that are influencing the growth of the global mRNA vaccines and therapeutics market?
  • How is each segment of the market expected to grow during the forecast period from 2021 to 2031? Following are the segment types:

Application

mRNA Type

Region

  • What are the unmet needs currently existing in the global mRNA vaccines and therapeutics market?

Market Overview

BIS healthcare experts have found the mRNA vaccines and therapeutics market to be one of the most rapidly evolving and dynamic markets, and the global market for mRNA vaccines and therapeutics for COVID-19 vaccines is predicted to grow at a CAGR of -13.50% over the forecast period of 2021-2025. Moreover, the global market for mRNA vaccines and therapeutics for non-COVID-19 vaccines is predicted to grow at a CAGR of 95.49% over the forecast period of 2026-2031. The overall global mRNA vaccines and therapeutics market is driven by certain factors, which include growing cases of COVID-19 globally, a favorable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines.

The growth of the market is favored by the developments in the field of mRNA-based COVID-19 vaccines due to the growing cases of COVID-19 globally, favourable regulatory environment, and significant external funding for the development of mRNA-based COVID-19 vaccines. Additionally, the emergence of the new SARS-CoV-2 virus in different countries, coupled with the efficacy of mRNA vaccines against new strains, are some of the critical factors which are expected to bolster the market growth. Furthermore, pharmaceutical companies are focusing on the development of new mRNA-based vaccine candidates for COVID-19 to support the healthcare authorities and the government to establish robust vaccination strategies.

The market for mRNA vaccines and therapeutics for non-COVID-19 is favored by the clinical developments which have been taking place to develop novel mRNA-based vaccines and therapies for non-COVID-19 applications, particularly for infectious disease, oncology, and other diseases. The emerging and legacy pharmaceutical companies are massively investing in the development of these treatment modalities to further expand their pipeline. The successful launch of these candidates after obtaining regulatory approvals from the regulatory authorities is anticipated to increase the competitiveness of the market.

Within the research report, the market is segmented on the basis of applications, mRNA type, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of COVID-19 cases followed by the growing emphasis of the government for establishing robust vaccination strategies has created a buzz among the pharmaceutical companies to further invest in the development of mRNA-based vaccines for COVID-19. Additionally, due to the growing prominence of mRNA vaccines, pharmaceutical companies are also significantly investing to expand their respective pipeline for non-COVID-19 applications such as infectious diseases, oncology, and other diseases. Due to the presence of a diverse portfolio and intense market penetration, BioNTech SE has been a pioneer in the mRNA vaccines and therapeutics ecosystem.

On the basis of region, North America holds the largest share of the mRNA vaccines and therapeutics market for COVID-19 vaccines due to significantly growing fund infusions for mRNA vaccine development, high rise in the pipeline products, presence of established and emerging pharmaceutical companies, presence of ultracold manufacturing and supply chains, and increasing awareness about mRNA-based COVID-19 vaccines, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest rate due to the exponentially rising cases of COVID-19 in the emerging countries, presence of a high population base in the region, and increasing demand for mRNA-based vaccines, among others.

Moreover, North America also holds the largest share of the mRNA vaccines and therapeutics market for non-COVID-19 vaccines due to the growing need to develop transformative therapeutics, increasing fund infusions, a favorable regulatory environment, and massively growing attention to establish precision medicine, among others.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusions and Exclusions

2 Market Scope

  • 2.1 Scope of Work
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global mRNA Vaccines and Therapeutics Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Market Overview

  • 4.1 Market Definition
  • 4.2 Current Landscape and Future Potential of mRNA-Based Vaccines
  • 4.3 Market Footprint and Growth Potential
    • 4.3.1 Global mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, 2020-2025
    • 4.3.2 Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-2031

5 Industry Insights

  • 5.1 Overview
  • 5.2 Legal Requirements and Frameworks in the U.S.
    • 5.2.1 Vaccines
      • 5.2.1.1 Pre-Clinical and Clinical Development
      • 5.2.1.2 Emergency Use Authorization (Public Health Emergencies)
      • 5.2.1.3 Assessment of Manufacturing
      • 5.2.1.4 Final Approval
    • 5.2.2 Therapeutics
      • 5.2.2.1 Clinical Trial Authorization
      • 5.2.2.2 Marketing Authorization
      • 5.2.2.3 Post-Authorization Regulations
  • 5.3 Legal Requirements and Frameworks in Europe
    • 5.3.1 Vaccines
    • 5.3.2 Therapeutics
      • 5.3.2.1 Centralized Procedure
      • 5.3.2.2 Decentralized Procedure
      • 5.3.2.3 Mutual-Recognition Procedure
      • 5.3.2.4 National Procedure
  • 5.4 Legal Requirements and Frameworks in Asia-Pacific
    • 5.4.1 China
    • 5.4.2 Japan

6 Market Dynamics

  • 6.1 Overview
  • 6.2 Impact Analysis
  • 6.3 Market Drivers
    • 6.3.1 Growing Cases of COVID-19 Globally
    • 6.3.2 Favorable Regulatory Environment
    • 6.3.3 Significant External Funding for the Development of mRNA-Based COVID-19 Vaccines
  • 6.4 Market Restraints
    • 6.4.1 Logistical Challenges Associated with mRNA-Based COVID-19 Vaccines
    • 6.4.2 High Price Associated with mRNA-Based COVID-19 Vaccines
  • 6.5 Opportunities
    • 6.5.1 Growing Emphasis on Research and Development for Non-COVID-19 Applications

7 Competitive Landscape

  • 7.1 Key Strategies and Developments
    • 7.1.1 Synergistic Activities
    • 7.1.2 Product Approvals and Commercialization
    • 7.1.3 Funding
  • 7.2 Market Share Analysis (by Company), 2020-2021

8 Global mRNA Vaccines and Therapeutics Market (by Application)

  • 8.1 COVID-19 mRNA Vaccines
    • 8.1.1 Overview
    • 8.1.2 Commercialized Vaccines
      • 8.1.2.1 mRNA-1273
        • 8.1.2.1.1 Supply Agreements for mRNA-1273
      • 8.1.2.2 BNT162b2
        • 8.1.2.2.1 Supply Agreements for BNT162b2 (COMIRNATY)
    • 8.1.3 Pipeline Vaccines
      • 8.1.3.1 CVnCoV
      • 8.1.3.2 LUNAR-COV19
      • 8.1.3.3 MRT5500
      • 8.1.3.4 DS-5670
  • 8.2 Non-COVID-19 mRNA Vaccines
    • 8.2.1 Overview
    • 8.2.2 Oncology
    • 8.2.3 Infectious Diseases
    • 8.2.4 Other Diseases

9 Global mRNA Vaccines and Therapeutics Market (by mRNA Type)

  • 9.1 Overview
  • 9.2 COVID-19 (by mRNA Type)
    • 9.2.1 Nucleoside-Modified mRNA (modRNA)
    • 9.2.2 Unmodified mRNA
    • 9.2.3 Self-Amplifying mRNA
  • 9.3 Non-COVID-19 (mRNA Type)
    • 9.3.1 Nucleoside-Modified mRNA (modRNA)
    • 9.3.2 Unmodified mRNA
    • 9.3.3 Self-Amplifying mRNA

10 Global mRNA Vaccines and Therapeutics Market (by Region)

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
      • 10.2.1.1 U.S.
      • 10.2.1.2 Canada
    • 10.2.2 North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
  • 10.3 Europe
    • 10.3.1 Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
      • 10.3.1.1 Germany
      • 10.3.1.2 France
      • 10.3.1.3 U.K.
      • 10.3.1.4 Italy
      • 10.3.1.5 Spain
      • 10.3.1.6 Rest-of-Europe
    • 10.3.2 Europe mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
  • 10.4 Asia-Pacific
    • 10.4.1 Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
      • 10.4.1.1 China
      • 10.4.1.2 Japan
      • 10.4.1.3 South Korea
      • 10.4.1.4 Australia
      • 10.4.1.5 Rest-of-Asia-Pacific
    • 10.4.2 Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
  • 10.5 Latin America
    • 10.5.1 Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
      • 10.5.1.1 Brazil
      • 10.5.1.2 Mexico
      • 10.5.1.3 Rest-of-Latin America
    • 10.5.2 Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
  • 10.6 Rest-of-the-World
    • 10.6.1 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines)
    • 10.6.2 Rest-of-the-World mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)

11 Company Profiles

  • 11.1 Overview
  • 11.2 Arcturus Therapeutics Holdings Inc.
    • 11.2.1 Company Overview
    • 11.2.2 Role of Arcturus Therapeutics Holdings Inc. in the Global mRNA Vaccines and Therapeutics Market
    • 11.2.3 Financials
    • 11.2.4 Key Insights About Financial Health of the Company
    • 11.2.5 SWOT Analysis
  • 11.3 BioNTech SE
    • 11.3.1 Company Overview
    • 11.3.2 Role of BioNTech SE in the Global mRNA Vaccines and Therapeutics Market
    • 11.3.3 Financials
    • 11.3.4 Key Insights About Financial Health of the Company
    • 11.3.5 SWOT Analysis
  • 11.4 CureVac N.V.
    • 11.4.1 Company Overview
    • 11.4.2 Role of CureVac N.V. in the Global mRNA Vaccines and Therapeutics Market
    • 11.4.3 Financials
    • 11.4.4 Key Insights About Financial Health of the Company
    • 11.4.5 SWOT Analysis
  • 11.5 Daiichi Sankyo Company, Limited.
    • 11.5.1 Company Overview
    • 11.5.2 Role of Daiichi Sankyo Company, Limited. in the Global mRNA Vaccines and Therapeutics Market
    • 11.5.3 Financials
    • 11.5.4 Key Insights About Financial Health of the Company
    • 11.5.5 SWOT Analysis
  • 11.6 ethris GmbH
    • 11.6.1 Company Overview
    • 11.6.2 Role of ethris GmbH in Global mRNA Vaccines and Therapeutics Market
    • 11.6.3 SWOT Analysis
  • 11.7 GlaxoSmithKline plc
    • 11.7.1 Company Overview
    • 11.7.2 Role of GlaxoSmithKline plc in Global mRNA Vaccines and Therapeutics Market
    • 11.7.3 Financials
    • 11.7.4 Key Insights About Financial Health of the Company
    • 11.7.5 SWOT Analysis
  • 11.8 Gennova Biopharmaceuticals Ltd
    • 11.8.1 Company Overview
    • 11.8.2 Role of Gennova Biopharmaceuticals Ltd in Global mRNA Vaccines and Therapeutics Market
    • 11.8.3 SWOT Analysis
  • 11.9 Moderna, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Role of Moderna, Inc. in the Global mRNA Vaccines and Therapeutics Market
    • 11.9.3 Financials
    • 11.9.4 Key Insights About Financial Health of the Company
    • 11.9.5 SWOT Analysis
  • 11.1 Pantherna Therapeutics GmbH
    • 11.10.1 Company Overview
    • 11.10.2 Role of Pantherna Therapeutics GmbH in Global mRNA Vaccines and Therapeutics Market
    • 11.10.3 SWOT Analysis
  • 11.11 Providence Therapeutics
    • 11.11.1 Company Overview
    • 11.11.2 Role of Providence Therapeutics in Global mRNA Vaccines and Therapeutics Market
    • 11.11.3 SWOT Analysis
  • 11.12 Silence Therapeutics
    • 11.12.1 Company Overview
    • 11.12.2 Role of Silence Therapeutics in the Global mRNA Vaccines and Therapeutics Market
    • 11.12.3 Financials
    • 11.12.4 Key Insights About Financial Health of the Company
    • 11.12.5 SWOT Analysis
  • 11.13 Translate Bio
    • 11.13.1 Company Overview
    • 11.13.2 Role of Translate Bio in the Global mRNA Vaccines and Therapeutics Market
    • 11.13.3 Financials
    • 11.13.4 Key Insights About Financial Health of the Company
    • 11.13.5 SWOT Analysis
  • 11.14 VERSAMEB AG
    • 11.14.1 Company Overview
    • 11.14.2 Role of VERSAMEB AG in the Global mRNA Vaccines and Therapeutics Market
    • 11.14.3 SWOT Analysis
  • 11.15 Verve Therapeutics, Inc.
    • 11.15.1 Company Overview
    • 11.15.2 Role of Verve Therapeutics, Inc. in the Global mRNA Vaccines and Therapeutics Market
    • 11.15.3 SWOT Analysis

List of Tables

  • Table 6.1: Likert Scale
  • Table 6.2: Impact Analysis of Market Drivers
  • Table 6.3: Impact Analysis of Market Restraints
  • Table 8.1: mRNA Vaccines and Therapeutics for Oncology (Pipeline)
  • Table 8.2: mRNA Vaccines and Therapeutics for Infectious Diseases (Pipeline)
  • Table 8.3: mRNA Vaccines and Therapeutics for Other Diseases (Pipeline)

List of Figures

  • Figure 1: Cumulative COVID-19 Cases (as of April 18, 2021)
  • Figure 2: Impact Analysis of Market Drivers and Market Challenges on Global mRNA Vaccines and Therapeutics Market
  • Figure 3: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Commercialized), Q4 2020 Vs. Q4 2025
  • Figure 4: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (Pipeline), Q2 2021 Vs. Q4 2025
  • Figure 5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (Pipeline), 2025 Vs. 2031
  • Figure 6: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)
  • Figure 7: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020-2025
  • Figure 8: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025-2031
  • Figure 2.1: Global mRNA Vaccines and Therapeutics, Market Segmentation
  • Figure 3.1: Global mRNA Vaccines and Therapeutics Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
  • Figure 4.1: Global Revenue for COVID-19 mRNA Vaccines, 2020-2025
  • Figure 4.2: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031
  • Figure 5.1: Steps for Obtaining Marketing Authorization
  • Figure 5.2: Vaccine Development Stages
  • Figure 5.3: Steps for Obtaining EMA Approval for Vaccines
  • Figure 6.1: Cumulative COVID-19 Cases (as of April 18, 2021)
  • Figure 6.2: Logistical Challenge Pertaining to mRNA-Based COVID-19 Vaccines
  • Figure 7.1: Share of Key Developments and Strategies, January 2018-March 2021
  • Figure 7.2: Share of Synergistic Activities (by Company), January 2018-March 2021
  • Figure 7.3: Share of Product Approvals and Commercialization (by Company), January 2018-March 2021
  • Figure 7.4: Share of Funding (by Company), January 2018-March 2021
  • Figure 7.5: Market Share Analysis for Global mRNA Vaccines and Therapeutics Market, 2020 and 2021
  • Figure 8.1: Global Revenue for COVID-19 mRNA Vaccines, $Million, 2020-2025
  • Figure 8.2: Global Revenue for COVID-19 mRNA Vaccines (Commercialized), $Million, Q4 2020-Q4 2025
  • Figure 8.3: Global Revenue for COVID-19 mRNA Vaccines (mRNA-1273), $Million, Q4 2020-Q4 2025
  • Figure 8.4: Global Revenue for COVID-19 mRNA Vaccines (BNT162b2), $Million, Q4 2020-Q4 2025
  • Figure 8.5: Expected Revenue from mRNA-Based COVID-19 Vaccines (Pipeline), $Million, Q4 2020-Q4 2025
  • Figure 8.6: Global Estimated Revenue for CVnCoV, $Million, Q2 2021- Q4 2025
  • Figure 8.7: Global Estimated Revenue for LUNAR-COV19, $Million, Q3 2022-Q4 2025
  • Figure 8.8: Global Estimated Revenue for MRT5500, $Million, Q4 2022-Q4 2025
  • Figure 8.9: Global Estimated Revenue for DS-5670, $Million, Q4 2022-Q4 2025
  • Figure 8.10: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines)
  • Figure 8.11: Global mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), 2025-2031
  • Figure 8.12: Global mRNA Vaccines and Therapeutics Market (Oncology), $Million, 2025-2031
  • Figure 8.13: Global mRNA Vaccines and Therapeutics Market (Infectious Diseases), $Million, 2025-2031
  • Figure 8.14: Global mRNA Vaccines and Therapeutics Market (Other Diseases), $Million, 2025-2031
  • Figure 9.1: Global mRNA Vaccines and Therapeutics Market (by mRNA Type)
  • Figure 9.2: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Nucleoside-Modified mRNA), $Million, Q42020-Q42025
  • Figure 9.3: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Unmodified mRNA), $Million, Q2 2021-Q4 2025
  • Figure 9.4: Global mRNA Vaccines and Therapeutics Market for COVID-19 (Self-Amplifying mRNA), $Million, Q3 2022-Q4 2025
  • Figure 9.5: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Nucleoside-Modified mRNA), $Million, 2025-2031
  • Figure 9.6: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Unmodified mRNA), $Million, 2025-2031
  • Figure 9.7: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 (Self-Amplifying mRNA), $Million, 2029-2031
  • Figure 10.1: Global mRNA Vaccines and Therapeutics Market for COVID-19 Vaccines (by Region), 2020 and 2025
  • Figure 10.2: Global mRNA Vaccines and Therapeutics Market for Non-COVID-19 Vaccines (by Region), 2025 and2031
  • Figure 10.3: North America: Market Dynamics
  • Figure 10.4: North America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020 vs. Q4 2025
  • Figure 10.5: North America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025
  • Figure 10.6: U.S. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.7: Canada mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.8: North America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2025-2031
  • Figure 10.9: Europe: Market Dynamics
  • Figure 10.10: Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.11: Europe mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q4 2020 vs. Q4 2025
  • Figure 10.12: Germany mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.13: France mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.14: U.K. mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.15: Italy mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.16: Spain mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.17: Rest-of-Europe mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2020-Q4 2025
  • Figure 10.18: Europe mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2025-2031
  • Figure 10.19: Asia-Pacific: Market Dynamics
  • Figure 10.20: Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.21: Asia-Pacific mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025
  • Figure 10.22: China mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025
  • Figure 10.23: Japan mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.24: South Korea mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q2 2021-Q4 2025
  • Figure 10.25: Australia mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.26: Rest-of-Asia-Pacific mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.27: Asia-Pacific mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031
  • Figure 10.28: Latin America: Market Dynamics
  • Figure 10.29: Latin America mRNA Vaccines and Therapeutics Market (COVID-19 Vaccines), (by Country), $Million, Q1 2021 vs. Q4 2025
  • Figure 10.30: Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.31: Brazil mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.32: Mexico mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.33: Rest-of-Latin America mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q1 2021-Q4 2025
  • Figure 10.34: Latin America mRNA Vaccines and Therapeutics Market (by Non-COVID-19 Vaccines), $Million, 2026-2031
  • Figure 10.35: Rest-of-the-World mRNA Vaccines and Therapeutics Market (by COVID-19 Vaccines), $Million, Q4 2020-Q4 2025
  • Figure 10.36: Rest-of-the-World mRNA Vaccines and Therapeutics (by Non-COVID-19 Vaccines), $Million, 2026-2031
  • Figure 11.1: Total Number of Companies Profiled
  • Figure 11.2: Arcturus Therapeutics Holdings Inc.: Pipeline Portfolio
  • Figure 11.3: Arcturus Therapeutics Holdings Inc.: Overall Financials, 2018-2020
  • Figure 11.4: Arcturus Therapeutics Holdings Inc.: R&D Expenditure, 2018-2020
  • Figure 11.5: Arcturus Therapeutics Holdings Inc.: SWOT Analysis
  • Figure 11.6: BioNTech SE: Product Portfolio
  • Figure 11.7: BioNTech SE: Pipeline Portfolio
  • Figure 11.8: BioNTech SE: Overall Financials, 2018-2020
  • Figure 11.9: BioNTech SE: Revenue (by Segment), 2018-2020
  • Figure 11.10: BionNTech SE: R&D Expenditure, 2018-2020
  • Figure 11.11: BioNTech SE: SWOT Analysis
  • Figure 11.12: CureVac N.V.: Pipeline Portfolio
  • Figure 11.13: CureVac N.V.: Overall Financials, 2018-2019
  • Figure 11.14: CureVac N.V.: Revenue (by Region), 2018-2019
  • Figure 11.15: CureVac N.V.: R&D Expenditure, 2018-2019
  • Figure 11.16: CureVac N.V.: SWOT Analysis
  • Figure 11.17: Daiichi Sankyo Company, Limited: Pipeline Portfolio
  • Figure 11.18: Daiichi Sankyo Company, Limited: Overall Financials, 2017-2019
  • Figure 11.19: Daiichi Sankyo Company, Limited.: Revenue (by Segment), 2017-2019
  • Figure 11.20: Daiichi Sankyo Company, Limited.: Revenue (by Region), 2017-2019
  • Figure 11.21: Daiichi Sankyo Company, Limited: R&D Expenditure, 2017-2019
  • Figure 11.22: Daiichi Sankyo Company, Limited.: SWOT Analysis
  • Figure 11.23: ethris GmbH: Pipeline Portfolio
  • Figure 11.24: ethris GmbH: SWOT Analysis
  • Figure 11.25: GlaxoSmithKline plc: Pipeline Portfolio
  • Figure 11.26: GlaxoSmithKline plc: Overall Financials, 2018-2020
  • Figure 11.27: GlaxoSmithKline plc: Revenue (by Segment), 2018-2020
  • Figure 11.28: GlaxoSmithKline plc: Revenue (by Region), 2018-2020
  • Figure 11.29: GlaxoSmithKline plc: R&D Expenditure, 2018-2020
  • Figure 11.30: GlaxoSmithKline plc: SWOT Analysis
  • Figure 11.31: Gennova Biopharmaceuticals Ltd: Pipeline Portfolio
  • Figure 11.32: Gennova Biopharmaceuticals Ltd: SWOT Analysis
  • Figure 11.33: Moderna, Inc.: Product Portfolio
  • Figure 11.34: Moderna, Inc: Pipeline Portfolio
  • Figure 11.35: Moderna, Inc.: Overall Financials, 2018-2020
  • Figure 11.36: Moderna, Inc.: Revenue (by Segment), 2018-2020
  • Figure 11.37: Moderna, Inc.: Revenue (by Region), 2020
  • Figure 11.38: Moderna, Inc.: R&D Expenditure, 2018-2020
  • Figure 11.39: Moderna, Inc.: SWOT Analysis
  • Figure 11.40: Pantherna Therapeutics GmbH: Pipeline Portfolio
  • Figure 11.41: Pantherna Therapeutics GmbH: SWOT Analysis
  • Figure 11.42: Providence Therapeutics: Pipeline Portfolio
  • Figure 11.43: Providence Therapeutics: SWOT Analysis
  • Figure 11.44: Silence Therapeutics: Pipeline Portfolio
  • Figure 11.45: Silence Therapeutics: Overall Financials, 2019-2020
  • Figure 11.46: Silence Therapeutics: Revenue (by Segment), 2019-2020
  • Figure 11.47: Silence Therapeutics: Revenue (by Region), 2019-2020
  • Figure 11.48: Silence Therapeutics: R&D Expenditure, 2019-2020
  • Figure 11.49: Silence Therapeutics: SWOT Analysis
  • Figure 11.50: Translate Bio: Pipeline Portfolio
  • Figure 11.51: Translate Bio: Overall Financials, 2018-2020
  • Figure 11.52: Translate Bio: R&D Expenditure, 2018-2020
  • Figure 11.53: Translate Bio: SWOT Analysis
  • Figure 11.54: VERSAMEB AG: Pipeline Portfolio
  • Figure 11.55: VERSAMEB AG: SWOT Analysis
  • Figure 11.56: Verve Therapeutics, Inc.: Pipeline Portfolio
  • Figure 11.57: Verve Therapeutics, Inc.: SWOT Analysis